Lucid Diagnostics Inc. (LUCD)

Market Cap	125.19M
Revenue (ttm)	4.35M
Net Income (ttm)	-53.03M
Shares Out	103.46M
EPS (ttm)	-1.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	783,369
Open	1.095
Previous Close	1.090
Day's Range	1.095 - 1.235
52-Week Range	0.630 - 1.800
Beta	1.26
Analysts	Strong Buy
Price Target	3.75 (+212.5%)
Earnings Date	May 12, 2025

About LUCD

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in a...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Oct 14, 2021
• Employees: 72
• Stock Exchange: NASDAQ
• Ticker Symbol: LUCD
• Website: https://www.luciddx.com

Financial Performance

In 2024, Lucid Diagnostics's revenue was $4.35 million, an increase of 79.00% compared to the previous year's $2.43 million. Losses were -$53.03 million, 0.68% more than in 2023.

Analyst Forecast

According to 4 analysts, the average rating for LUCD stock is "Strong Buy." The 12-month stock price forecast is $3.75, which is an increase of 212.50% from the latest price.

Price Target

$3.75

(212.50% upside)

Analyst Consensus: Strong Buy